Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 06  •  04:00PM ET
8.91
Dollar change
-7.09
Percentage change
-44.31
%
Index- P/E- EPS (ttm)-0.17 Insider Own49.42% Shs Outstand47.34M Perf Week-
Market Cap421.80M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float23.95M Perf Month-
Enterprise Value416.05M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Income-8.21M P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Sales0.00M P/B79.57 EPS next Y- ROA- Short Interest- Perf YTD-74.54%
Book/sh0.11 P/C73.36 EPS next 5Y- ROE- 52W High48.91 -81.78% Perf Year-
Cash/sh0.12 P/FCF- EPS past 3/5Y- - ROIC-154.93% 52W Low13.05 -31.72% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility- - Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM- Oper. Margin- ATR (14)14.33 Perf 10Y-
Dividend Ex-Date- Quick Ratio8.77 Sales Y/Y TTM- Profit Margin- RSI (14)- Recom-
Dividend Gr. 3/5Y- - Current Ratio8.77 EPS Q/Q-85.28% SMA20-57.31% Beta- Target Price-
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-57.31% Rel Volume6.34 Prev Close16.00
Employees- LT Debt/Eq0.00 Earnings- SMA200-57.31% Avg Volume29.27K Price8.91
IPOFeb 02, 2026 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume185,635 Change-44.31%
Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.